Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/ddr.21701

http://scihub22266oqcxt.onion/10.1002/ddr.21701
suck pdf from google scholar
32524646!7307055!32524646
unlimited free pdf from europmc32524646    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32524646  :  Publisher

suck abstract from ncbi

pmid32524646
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Lithium as a candidate treatment for COVID-19: Promises and pitfalls #MMPMID32524646
  • Rajkumar RP
  • Drug Dev Res 2020[Nov]; 81 (7): 782-785 PMID32524646show ga
  • The pandemic of respiratory illness caused by a novel coronavirus (SARS-nCoV-2) is a global health crisis. Despite numerous preliminary results, there is as yet no treatment of proven efficacy for this condition. In this context, the pharmacological properties of lithium, better known as a treatment for mood disorders, merit closer examination. Lithium has shown in vitro efficacy at inhibiting the replication of coronaviruses responsible for gastrointestinal and respiratory diseases in animals. It has immunomodulatory properties that may be of additional benefit in moderating the host inflammatory response to the novel coronavirus (SARS-CoV-2). Furthermore, there is evidence that lithium may exert a protective action against upper respiratory infections and influenza-like illnesses in patients taking it for other indications. These promising reports must be balanced against the narrow therapeutic index and high risk of toxicity associated with lithium therapy, its documented interactions with several commonly used drugs, and the absence of evidence of its efficacy against coronaviruses responsible for human disease. Nevertheless, naturalistic studies of the risk of COVID-19 in patients already receiving lithium could provide indirect evidence of its efficacy, and understanding the putative antiviral and immune-regulatory mechanisms of lithium in models of SARS-CoV-2 infection may provide leads for the development of safer and more effective treatments with a specific action against COVID-19.
  • |Animals[MESH]
  • |Antiviral Agents/pharmacology/*therapeutic use[MESH]
  • |COVID-19/*drug therapy[MESH]
  • |Lithium/pharmacology/*therapeutic use[MESH]
  • |Pragmatic Clinical Trials as Topic[MESH]
  • |SARS-CoV-2/drug effects[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    782 7.81 2020